Stock Performance

0.36
0.00

Back to OBR Finance »

Cell Genesys Inc. (CEGE)
Oncology Corporate Profile

  • Products & Overview
  • Recent News

HQ Location

500 Forbes Boulevard
South San Francisco, CA 94080

Company Description

Cell Genesys is a biotechnology company that engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies.

Website: http://www.cellgenesys.com

Commercial Products

This company does not have any commercial products

Pipeline Products

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GVAX vaccineimmunotherapyLeukemiaIITakeda
GVAX vaccineimmunotherapyPancreatic cancerIITakeda
CG0070oncolytic virusBladder cancerINovartis AG
GVAX vaccineimmunotherapyNon Small Cell Lung Cancer (NSCLC)PreclinicalTakeda

View additional information on product candidates here »


Recent News Headlines

BioSante Pharmaceuticals said Thursday that its GVAX cancer treatment led to a reduction of cancer cells in leukemia patients who had been taking the cancer drug Gleevec for at least one year.

BioSante Pharmaceuticals Inc. said Wednesday that it completed an all-stock buyout of Cell Genesys Inc. and the combined company will focus on developing a topical testosterone gel intended to treat sexual dysfunction in women.

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.

BioSante Pharmaceuticals Inc. said it is adjusting its exchange ratio with Cell Genesys Inc. as the companies prepare to complete their all-stock tie up.

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced merger between the companies.

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. , today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.

Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease.

SOUTH SAN FRANCISCO, Calif.----Cell Genesys, Inc. today reported financial results for the second quarter 2009. The company reported a net loss of $3.8 million , for the second quarter of 2009, compared to a net loss of $2.8 million for the corresponding period in 2008.